
News|Articles|March 1, 2002
Eligard 7.5 mg (Leuprolide acetate 7.5 mg for subcutaneous injection), Atrix/Sanofi-Synthelabo
New formulation: Monthly SC injection form of GnRH agonist for advanced prostate cancer
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends
4
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
5


























